期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 6, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s40425-018-0342-x
关键词
DNA mismatch repair; Microsatellite instability; Pembrolizumab; Biomarker; Immunotherapy
资金
- NATIONAL CANCER INSTITUTE [ZIABC010666] Funding Source: NIH RePORTER
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti-programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据